Abstracts tagged "spondyloarthritis"

Abstract Number: 0519 • ACR Convergence 2023
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension
Atul Deodhar¹, Victoria Navarro-Compán², Denis Poddubnyy³, Lianne Gensler⁴, Sofia Ramiro⁵, Tetsuya Tomita⁶, Helena Marzo-Ortega⁷, Carmen Fleurinck⁸, Thomas Vaux⁹, Ute Massow¹⁰, Désirée van der Heijde⁵ and Xenofon Baraliakos¹¹, ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Graduate School of Health Science, Morinomiya University of Medical Science, Osaka, Japan, ⁷NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim am Rhein, Germany, ¹¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody, selectively inhibits IL-17F in addition to IL17A. BKZ has demonstrated clinical efficacy and safety up to 3 years…
Abstract Number: 0746 • ACR Convergence 2023
The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis
Jessica Gutierrez Manjarrez¹, Sydney Thib², Richard J. Cook³ and Lihi Eder⁴, ¹Women’s College Research Institute / Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Women’s College Research Institute, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Ultrasound (US) may improve characterization of psoriatic arthritis (PsA) phenotypes and help predict disease outcomes. We aimed to assess whether US phenotypes are associated…
Abstract Number: 1385 • ACR Convergence 2023
Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers
Joerg Ermann¹, Stephanie Sinnappan² and Alexandra Forte³, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Several sets of treatment recommendations for axial spondyloarthritis and ankylosing spondylitis (axSpA/AS) have been published. Clinical practice guidelines are not followed consistently by health…
Abstract Number: 1415 • ACR Convergence 2023
Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
Philip J. Mease¹, Dafna Gladman², Laure Gossec³, Peter Nash⁴, Barbara Ink⁵, Jason Coarse⁶, Nikos Lyris⁵, Damon Willems⁷ and William R Tillett⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ⁴School of Medicine, Griffith University, Brisbane, Australia, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Brussels, Belgium, ⁸Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA impacts the physical health and functional ability of patients (pts),which can contribute to reduced work productivity.1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody…
Abstract Number: 1872 • ACR Convergence 2023
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Joeri Nicolaes¹, Evi Tselenti², Theodore Aouad³, Clementina López Medina⁴, Antoine Feydy⁵, Hugues Talbot³, Bengt Hoepken⁶, Natasha De Peyrecave⁷ and Maxime Dougados⁸, ¹KU Leuven, Department of Electrical Engineering (ESAT), Center for Processing Speech and Images; UCB Pharma, Anderlecht, Belgium, ²Veramed, London, United Kingdom, ³CentraleSupélec, Universite Paris-Saclay, Inria, Gif-sur-Yvette, France, ⁴Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ⁵INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Radiology Department, Cochin Hospital, Paris, France, ⁶UCB Pharma, Monheim, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France
Background/Purpose: Magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) is an essential tool in the evaluation of patients with axial spondyloarthritis (axSpA). In-depth knowledge…
Abstract Number: 2204 • ACR Convergence 2023
Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA)
Denis Choquette¹, Walter P. Maksymowych², Proton Rahman³, Robert Inman⁴, Marie-Claude Laliberté⁵, Pierre-Andre Fournier⁶, Tanya Girard⁵ and Dafna Gladman⁷, ¹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵AbbVie, Inc., Saint-Laurent, QC, Canada, ⁶AbbVie, Inc., Montréal, QC, Canada, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: In patients with axial spondyloarthritis (axSpA), treatment goals consist of achieving remission or low disease activity (LDA) to alleviate symptoms, improve function, decrease disease…
Abstract Number: 2222 • ACR Convergence 2023
Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides
Juliane Michel¹, Clément Prati², Lucine Vuitton³, Eric Toussirot⁴, Charline Vauchy⁵, Daniel Wendling⁶ and frank Verhoeven², ¹Rheumatology, CHU Besancon, Besançon, France, ²Service de rhumatologie, CHU de Besançon, Besançon, France, ³Gastroenterology, CHU Besancon, Besançon, France, ⁴University Hospital of Besancon, Besançon, France, ⁵INSERM CIC-1431, Besançon, France, ⁶Besançon University Hospital, Besançon, France
Background/Purpose: There is a pathophysiological link between spondyloarthritis (SpA) and Inflammatory Bowel Disease (IBD), so that 10% of IBD is estimated to have SpA and…
Abstract Number: 0356 • ACR Convergence 2023
PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis
Pamela F. Weiss¹, Timothy G. Brandon², Amita Aggarwal³, RUBEN BURGOS-VARGAS⁴, Robert Colbert⁵, Gerd Horneff⁶, Rik Joos⁷, Ronald Laxer⁸, Kirsten Minden⁹, Angelo Ravelli¹⁰, Nicolino Ruperto¹¹, Judith Smith¹², Matthew Stoll¹³, Shirley Tse⁸, Filip Van den Bosch¹⁴, Walter P. Maksymowych¹⁵, Robert Lambert¹⁶, David Biko², Nancy A. Chauvin¹⁷, Michael L. Francavilla¹⁸, Jacob Jaremko¹⁵, Nele Herregods¹⁹, Ozgur Kasapcopur²⁰, Mehmet YILDIZ²¹, Hemalatha Srinivasalu²², Ray Naden²³ and Alison Hendry²⁴, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁴Hospital General de Mexico, Ciudad de México, Mexico, ⁵NIH/NIAMS, Bethesda, MD, ⁶Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ⁷Ghent University, Basel, Switzerland, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ¹⁰Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹¹IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ¹²University of Wisconsin, Madison, WI, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ¹⁵University of Alberta, Edmonton, AB, Canada, ¹⁶Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ¹⁷The Cleveland Clinic, Hummelstown, PA, ¹⁸University of South Alabama College of Medicine, Mobile, AL, ¹⁹Ghent University Hospital, Ghent, Belgium, ²⁰Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²¹Istanbul University-Cerrahpasa Department of Pediatric Rheumatology, Istanbul, Turkey, ²²Children's National Hospital, Washington, DC, ²³Auckland City Hospital, Auckland, New Zealand, ²⁴Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand
Background/Purpose: The Paediatric Rheumatology International Trials Organisation (PRINTO) recently undertook an effort to better harmonize the pediatric and adult arthritis criteria. These provisional criteria are…
Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Martin Rudwaleit¹, Victoria Navarro-Compán², Atul Deodhar³, Maureen Dubreuil⁴, Michael Frank Mørup⁵, Vanessa Taieb⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Thomas Vaux¹⁰ and Annelies Boonen¹¹, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁵UCB Pharma, Copenhagen, Denmark, ⁶UCB Pharma, Colombes, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…
Abstract Number: 0824 • ACR Convergence 2023
Defining Poor Global Functioning and Health in Axial Spondyloarthritis, Using the EQ-5D-3L Questionnaire, When the ASAS-Health Index Is Not Available Is Feasible. an Analysis of 2651 Patients from the PERSPA Study
Juliette Drouet¹, Clementina López Medina², Anna Molto³, Benjamin Granger¹, Bruno Fautrel⁴, Cécile Gaujoux Viala⁵, Uta Kiltz⁶, Maxime Dougados⁷ and Laure Gossec⁸, ¹Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Sorbonne Université APHP, Paris, France, ⁵IDESP Univ Montpellier, INSERM, Rheumatology, CHU Nîmes, Montpellier, France, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ⁸Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: In axial Spondyloarthritis (axSpA) it is recommended to assess global functioning and health, a concept close to health-related quality of life (HR-QoL), using the…
Abstract Number: 1389 • ACR Convergence 2023
Low Spinal Radiographic Progression After a Mean of 15 Years of Follow-up in a Cohort of Patients with Axial Spondyloarthritis
raquel granados¹, Santiago Dans-Caballero¹, Lourdes Ladehesa Pineda², María Ángeles Puche Larrubia³, Desiree Ruiz Vilchez⁴, Maria del Carmen Abalos-Aguilera⁴, Alejandro Escudero-Contreras⁵, Eduardo Collantes Estévez⁶ and Clementina López Medina⁷, ¹Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain, ²Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ³Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁵Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ⁶Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ⁷Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by progressive structural damage on the sacroiliac joints and/or the spine. Conventional radiology allows to assess radiology through available…
Abstract Number: 1433 • ACR Convergence 2023
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Joseph Merola¹, Philip J. Mease², Atul Deodhar³, Barbara Ink⁴, Carmen Fleurinck⁵, Rajan Bajracharya⁴, Jason Coarse⁶ and Laura Coates⁷, ¹Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…
Abstract Number: 1873 • ACR Convergence 2023
Cervical Spine Involvement in Axial Spondyloarthritis. Radiographic Characteristics and Associated Factors
pol Maymó¹, Laura Berbel Arcobé², Xabi Michelena³, José Antonio Narvaez², Joan Miquel Nolla⁴, Lídia Valencia², Judith Palacios⁴ and Xavier Juanola Roura¹, ¹Hospital Universitari de Bellvitge, Barcelona, Spain, ²H.U. Bellvitge, Barcelona, Spain, ³Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ⁴Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: The study of the cervical spine (CS) in axial spondyloarthritis (axSpA) and its radiographic characteristics including the zygapophyseal joints (ZJ) may be helpful for…
Abstract Number: 2205 • ACR Convergence 2023
Disease Activity and Widespread Pain Are the 2 Key Drivers of Global Health in Axial Spondyloarthritis, with Similar Findings in Different Patient Populations: An Analysis of 4 Databases and 6064 Patients
Juliette Drouet¹, Clementina López Medina², Benjamin Granger¹, Bruno Fautrel³, Anna Molto⁴, Cécile Gaujoux Viala⁵, Uta Kiltz⁶, Maxime Dougados⁷ and Laure Gossec⁸, ¹Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ³Sorbonne Université APHP, Paris, France, ⁴HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵IDESP Univ Montpellier, INSERM, Rheumatology, CHU Nîmes, Montpellier, France, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ⁸Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease affecting global functioning and health (GH). GH, a concept linked to health-related quality of life, is…
Abstract Number: 2223 • ACR Convergence 2023
Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study
Srujana Budumuru, Rohini Handa, Sundeep Kumar Upadhyaya, Sirinder Jit Gupta, Meera H Shah, Meera P Shah and Anushka Aggarwal, Indraprastha Apollo Hospital, Delhi, India
Background/Purpose: Sleep problems are prevalent in 30-70% of patients with axial Spondyloarthritis (SpA), negatively impacting their quality of life. Poor sleep quality in these patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].